Abstract:The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (MM) makes this tumor type an ideal candidate for p53-targeted therapies. RITA is a small molecule which can induce apoptosis in tumor cells by activating the p53 pathway. We previously showed that RITA strongly activates p53 while selectively inhibiting growth of MM cells without inducing genotoxicity, indicating its potential as a drug lead for p53-targeted therapy in MM. However, the molecular mechanisms underlying the pro-apoptotic effect of RITA are largely undefined. Gene expression analysis by microarray identified a significant number of differentially expressed genes associated with stress response including c-Jun N-terminal kinase (JNK) signaling pathway. By Western blot analysis we further confirmed that RITA induced activation of p53 in conjunction with up-regulation of phosphorylated ASK-1, MKK-4 and c-Jun. These results suggest that RITA induced the activation of JNK signaling. Chromatin immunoprecipitation (ChIP) analysis showed that activated c-Jun binds to the activator protein-1 (AP-1) binding site of the p53 promoter region. Disruption of the JNK signal pathway by small interfering RNA (siRNA) against JNK or JNK specific inhibitor, SP-600125 inhibited the activation of p53 and attenuated apoptosis induced by RITA in myeloma cells carrying wild type p53. On the other hand, p53 transcriptional inhibitor, PFT-α or p53 siRNA not only inhibited the activation of p53 transcriptional targets but also blocked the activation of c-Jun suggesting the presence of a positive feedback loop between p53 and JNK. In addition, RITA in combination with dexamethasone, known as a JNK activator, displays synergistic cytotoxic responses in MM cell lines and patient samples. Our study unveils a previously undescribed mechanism of RITA-induced p53-mediated apoptosis through JNK signaling pathway and provides the rationale for combination of p53 activating drugs with JNK activators in the treatment of MM.

Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)

IC261, a Specific Inhibitor of CK1δ/ε, Promotes Aerobic Glycolysis Through P53-Dependent Mechanisms in Colon Cancer

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy

AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer

Decreased DNA Damage and Improved P53 Specificity of RITA Analogs

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

Abstract 3221: Targeting ARID1A-mutated gastric cancer cells with synthetic lethal approaches

The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis

Vulnerability of ARID1A deficient cancer cells to pyrimidine synthesis blockade

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response

Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer

Pan-cancer Analysis of ARID1A Alterations As Biomarkers for Immunotherapy Outcomes

Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro

ARID1A Loss Sensitizes Colorectal Cancer Cells to Floxuridine

Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis

Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based Screening

Targeting P53 Via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma

BRD4 Inhibition Induces Synthetic Lethality in ARID2 -Deficient Hepatocellular Carcinoma by Increasing DNA Damage

Research Progress of the Tumor Suppressor ARID1A

Tumor suppressor role of chromatin-remodeling factor ARID1A]